Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over

Ruxolitinib (Jakavi, Novartis) is indicated for 'the treatment of patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids'.

The dosage schedule is available in the summary of product characteristics for ruxolitinib.

The list price for a 56-tablet pack of 5 mg ruxolitinib is £1,428, and for a 56-tablet pack of 10 mg ruxolitinib is £2,856 (excluding VAT; BNF online, accessed March 2025).

The company has a commercial arrangement. This makes ruxolitinib available to the NHS with a discount. The size of the discount is commercial in confidence.